Ignite Creation Date:
2024-05-05 @ 6:59 PM
Last Modification Date:
2024-10-26 @ 9:40 AM
Study NCT ID:
NCT00585195
Status:
COMPLETED
Last Update Posted:
2023-02-08
First Post:
2007-12-29
Brief Title:
A Study Of Oral PF-02341066 A C-MetHepatocyte Growth Factor Tyrosine Kinase Inhibitor In Patients With Advanced Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
PHASE 1 SAFETY PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066 A METHGFR SELECTIVE TYROSINE KINASE INHIBITOR ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROFILE 1001
Brief Summary:
PF-02341066 may work in cancer by blocking the cell growth migration and invasion of tumor cells PF-02341066 is a new class of drugs called c-MetHepatocyte growth factor receptor tyrosine kinase inhibitors This compound is also an inhibitor of the anaplastic lymphoma kinase called ALK tyrosine kinase and ROS receptor tyrosine kinases This research study is the first time PF-02341066 will be given to people PF-02341066 is taken by mouth daily
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| PROFILE 1001 | OTHER | Alias Study Number | None |